Maher Hanoun

16PUBLICATIONS
99CO-AUTHORS
Haematological tumoursMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 13, 2026
IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Johanna M Horns, Thomas Beder, Axel Künstner

|Jan 06, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Stefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer

|Oct 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Marius Bill, Jan-Niklas Eckardt, Konstanze Döhner

|Jul 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch

|Nov 06, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Leo Ruhnke, Marius Bill, Sven Zukunft

|Apr 09, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.

Christoph Röllig, Christoph Schliemann, Leo Ruhnke

Pageof 3

Frequent Collaborators

11 joint publications

Stefan W Krause

10 joint publications

Christoph Röllig

9 joint publications

Christoph Schliemann

7 joint publications

Carsten Müller-Tidow